Tectonic Advisors LLC Cuts Stock Holdings in CVS Health Corporation $CVS

10 Oct 2025, 11:12 by Amy Steele · The Cerbat Gem

Tectonic Advisors LLC trimmed its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 11.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,985 shares of the pharmacy operator’s stock after selling 1,693 shares during the quarter. Tectonic Advisors LLC’s holdings in CVS Health were worth $896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Essex Financial Services Inc. boosted its position in shares of CVS Health by 0.8% during the first quarter. Essex Financial Services Inc. now owns 20,705 shares of the pharmacy operator’s stock valued at $1,403,000 after buying an additional 166 shares during the last quarter. Williams Financial LLC boosted its position in shares of CVS Health by 2.5% during the second quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator’s stock valued at $478,000 after buying an additional 167 shares during the last quarter. Hemington Wealth Management boosted its position in CVS Health by 33.7% in the first quarter. Hemington Wealth Management now owns 682 shares of the pharmacy operator’s stock worth $46,000 after purchasing an additional 172 shares during the last quarter. Sumitomo Life Insurance Co. boosted its position in CVS Health by 1.0% in the first quarter. Sumitomo Life Insurance Co. now owns 17,114 shares of the pharmacy operator’s stock worth $1,159,000 after purchasing an additional 174 shares during the last quarter. Finally, Koshinski Asset Management Inc. boosted its position in CVS Health by 3.7% in the first quarter. Koshinski Asset Management Inc. now owns 4,930 shares of the pharmacy operator’s stock worth $334,000 after purchasing an additional 178 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Down 0.2%

Shares of CVS opened at $76.78 on Friday. The business’s 50 day moving average is $71.98 and its 200 day moving average is $67.59. The company has a market capitalization of $97.38 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $79.20. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter in the previous year, the company posted $1.83 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. CVS Health’s payout ratio is 74.30%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CVS. Jefferies Financial Group raised their target price on CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 30th. Bernstein Bank dropped their target price on CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research report on Wednesday, July 16th. Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a research report on Saturday, September 27th. Wells Fargo & Company raised their target price on CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Morgan Stanley raised their target price on CVS Health from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.80.

Read Our Latest Report on CVS Health

Insider Transactions at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.22% of the stock is currently owned by insiders.

CVS Health Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.